CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Reporting to the Manager, Office of Compliance and Oversight (OCO), the Audit and Monitoring Group (AMG) Team Leader will lead one of the two teams in AMG, namely the Canadian On-Site Monitoring Team OR the Residual and International Monitoring Teams. The AMG Team Leader will ensure AMG standard operating procedures are followed to ensure compliance with applicable guidelines, regulations and standards.
The #CCTG2021 Virtual Spring Meeting is less than a month away!
The first round of invitations has been sent so check your inbox for your invitation email. If you cannot find your e-invitation in your inbox, please check your trash or spam folders. If you need to have your e-invitation re-sent please e-mail us at meeting.spring@ctg.queensu.ca.
Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.
Evaluate the ability to predict survival benefit from adjuvant chemotherapy in early stage non-small cell lung cancer (NSCLC), and
The MAC9 (S0307) PHASE III TRIAL OF BISPHOSPHONATES AS ADJUVANT THERAPY FOR PRIMARY BREAST CANCER trial has been permanently closed.
PURPOSE: This randomized phase III trial studied zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
CCTG is currently recruiting for a Regulatory Affairs Team Leader and a Cancer Research Monitor/Auditor to join our central offices at Queen's University in Kingston Ontario.
A new nation-wide study examines how COVID-19 is impacting cancer patients and survivors
March 12, 2021 By Jennifer Friesen
There’s no question that 2020 was a challenging year. Today, the effects of COVID-19 continue to echo around the world, impacting people’s lives, livelihoods and social connections.
In addition to navigating all this global uncertainty, an estimated 225,000 Canadians also faced a cancer diagnosis last year.
